Navigation Links
Key to treating cancer may be finding its original cell
Date:8/11/2008

DURHAM, N.C. Cancer biologists are turning their attention to the normal cells that give rise to cancers, to learn more about how tumor growth might be stopped at the earliest opportunity.

"Identifying the specific, normal cells that cancers come from can provide critical insight into how cancers develop," said Robert Wechsler-Reya, an associate professor of Pharmacology and Cancer Biology at Duke University Medical Center. "This may help us develop more rational and effective approaches to treatment."

Every cancer comes from a normal cell. The hard part is finding the cell at the root of each particular subtype of cancer. For the first time, the Duke team has identified two types of cells in the brain that can give rise to the malignant brain tumor medulloblastoma. This dangerous cancer, which occurs most commonly in children, is currently treated with a combination of surgery, chemotherapy and radiation, which have extremely severe side effects, said Wechsler-Reya, who is a member of the Preston Robert Tisch Brain Tumor Center at Duke.

To find the normal cells at the root of medulloblastoma, Wechsler-Reya's laboratory, in collaboration with Brandon Wainwright's laboratory at the University of Queensland in Australia, created mouse models of medulloblastoma by turning off the patched gene, a key regulator of cell growth in the developing brain cerebellum. In particular, they tested the effects of shutting off patched in granule neuron precursors (GNPs), which can only make one particular type of nerve cell (neuron), or in stem cells, which can make all the different cell types in the cerebellum.

When they deleted patched in the neuron precursors, 100 percent of the mice developed medulloblastoma. Deleting patched from stem cells initially led to the formation of many more stem cells. However, most of these stem cells went on to form normal cell types within the cerebellum. Only the patched-less stem cells that gave rise to GNPs went on to form medulloblastoma tumors.

According to Wechsler-Reya, these studies provide the first definitive proof that medulloblastoma can be triggered in a granule neuron precursor or a stem cell. But even more importantly, they suggest that when it comes to cancer formation, the cell type in which a mutation happens is as important as the mutation itself. Although stem cells that lack patched also gave rise to other forms of brain cells, those cells did not form the tumors.

"Simply mutating a gene is not enough to cause cancer," Wechsler-Reya said. "The mutation has to happen in the right cell type at the right time. In the case of patched, GNPs provide the critical context for tumor formation."

Wechsler-Reya said that cancer biologists need to learn more about the genes that regulate proliferation (cell division), differentiation, survival, and programmed cell death in normal cells. A mutation in a proliferation gene, for example, can send the cell on a path of exaggerated division of cells -- becoming a fast-growing tumor. Understanding the way these genes are controlled during normal development can shed light on how they go awry in human cancers.


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Study provides clues to preventing and treating cancer spread
2. Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments
3. Treating rare breast cancer with radiation therapy may lower recurrence rate
4. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
5. Louisiana Improves Law for Treating Mentally Ill
6. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
7. New system devised to guide doctors treating patients with symptomatic myocardial bridging
8. NACDS Praises House Legislation to Delay Medicaid Cuts, Aid Pharmacies in Treating Patients
9. Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
10. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
11. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Menopause market? What are the unit prices and annual ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology: